Last updated: 11/07/2018 11:49:57
Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study –
Trial description: The purpose of this study is to examine whether the VPA (Valproate) dose can be reduced by additional administration of LTG (Lamotrigine) in Japanese pre-menopausal female epilepsy patients aged 15 years or older, whose seizures are well controlled by VPA monotherapy.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Percentage of participants who achieved reduction in daily VPA dose
Timeframe: Baseline and at the end of the LTG and VPA Maintenance Phase, 24-46 weeks that can be varied by durations of the LTG Escalation Phase and VPA Reduction Phase
Percent change in the VPA dose
Timeframe: Baseline and at the end of the LTG and VPA Maintenance Phase, 24-46 weeks that can be varied by durations of the LTG Escalation Phase and VPA Reduction Phase
Secondary outcomes:
Number of days in total that epileptic seizures occurred up to the LTG and VPA Maintenance Phase
Timeframe: Baseline and up to 46 weeks
Change from Baseline in quality of life in epilepsy-31-P (QOLIE-31-P) in participants aged 18 years and older
Timeframe: Baseline and up to 46 weeks
Change from Baseline in quality of life in epilepsy for adolescents (QOLIE-AD-48) in participants aged 15-17 years
Timeframe: Baseline and up to 46 weeks
Percentage of participants who completed or discontinued from the study
Timeframe: Up to 50 weeks
Number of participants with adverse events (AEs), AEs leading to discontinuation of the investigational product and/or withdrawal from the study, drug-related AEs, deaths and serious adverse events (SAEs) throughout the study
Timeframe: From the start of study treatment until follow-up (up to 50 weeks)
Interventions:
Drug: Lamotrigine tablets 25/100 mg
Enrollment:
33
Observational study model:
Not applicable
Primary completion date:
2015-11-05
Time perspective:
Not applicable
Clinical publications:
Takamichi Yamamoto, Yuichi Kubota, Hirohiko Murayama, Hirofumi Ozeki, Yotaro Numachi, Akio Ikeda, on Behalf of the Lamictal 200776 Study Group. Appropriate conversion from valproate monotherapy to lamotrigine monotherapy in Japanese women with epilepsy. Epilepsy Seizure. 2016;8(1):21-31
Medical condition
Epilepsy
Product
lamotrigine, valproic acid
Collaborators
Not applicable
Study date(s)
April 2014 to May 2015
Type
Interventional
Phase
4
Participation criteria
Sex
Female
Age
15+ years
Accepts healthy volunteers
No
- 1.(Target disease)
- Epilepsy patients having the following seizure types as classified by the International Classification of Epileptic Seizures
- 1.Subjects with a history of hypersensitivity to LTG
- 2.Subjects with a history of rash associated with other AED treatments.
Inclusion and exclusion criteria
Inclusion criteria:
- 1.(Target disease) Epilepsy patients having the following seizure types as classified by the International Classification of Epileptic Seizures
- Partial seizures (with or without secondary generalization)
- Tonic-clonic seizures with or without myoclonus but without other generalized seizure type(s) 2.Subjects having a confident diagnosis of epilepsy that is uncomplicated by pseudoseizures such as psychogenic nonepileptic seizures 3.Subjects whose seizures have been controlled for 12 weeks prior to start of the investigational product with a stable maintenance dose of VPA monotherapy (400-1200 mg/d) 4.(Age and gender) Japanese pre-menopausal women who are at least 15 years old at the time of consent, not lactating, and can agree to use any of the following types of contraception in a reliable fashion: 1)Complete abstinence during the study as well as for a period after the study to account for elimination of the investigational product (a minimum of 2 weeks) 2)Consistent and correct use of any of the following contraceptive methods
- Surgical sterilization of male partner (i.e., male partner is the sole sexual partner for the female subject and is sterilized prior to the subject’s entry into the study)
- Intrauterine device with a failure rate of less than 1% per year
- Double barrier method (e.g., spermicide plus a condom or a diaphragm) Note: Women who have had a hysterectomy or tubal ligation are considered to be of non-childbearing potential. Since a pharmacokinetic interaction has been observed between LTG and estrogen-based oral contraceptives, the use of hormonal therapy such as for contraception or hormone replacement therapy is not allowed. 5.Outpatients 6.Subjects who can keep a seizure diary 7.Subjects who can understand and sign the informed consent. If the subject is under 20 years old at the time of consent, both the subject and subject’s legally acceptable representative have to sign the consent to participate in the study. 8.QTc <480 msec for subjects with bundle branch block or QTc <450 msec for other subjects, in which QTc is measured by either single or triplicate-averaged ECG 9.Subjects who can comply with dosing of the investigational and standard products and all study procedures
Exclusion criteria:
- 1.Subjects with a history of hypersensitivity to LTG 2.Subjects with a history of rash associated with other AED treatments. 3.Subjects who have received another AED besides VPA during the 12 weeks prior to start of the investigational product 4.Subjects with status epilepticus during the 6 months prior to start of the investigational product 5.Subjects with a history of substance (including alcohol and drug) dependence or substance abuse as defined by the DSM-IV-TR within 12 months or 1 month, respectively, prior to start of the investigational product 6.Subjects with a severe acute or chronic illness likely to impair drug absorption, distribution, metabolism, or excretion; or subjects with any unstable physical symptom likely to require hospitalization during the study 7.Subjects with a severe psychiatric disorder that affects the procedures of the study or drug assessment 8.Subjects with an acute or progressive neurological disorder or an organic disease 9.Subjects with any clinically significant cardiac, renal, or hepatic medical condition. Any patient with these conditions will be excluded from the study even if these conditions are being controlled with a chronic therapy. 10.Subjects with an unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, or known biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones) Note: Chronic stable hepatitis B and C are acceptable if the subjects otherwise meet the inclusion criteria. However, the subjects with chronic stable hepatitis B will be excluded if significant immunosuppressive agents are being administered due to a risk of hepatitis B reactivation. 11.Subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study 12.Subjects who are suspected to have an urea cycle disorder as below:
- Subjects with a history of encephalopathy or coma of unknown cause
- Subjects with a family history of infant death of unknown cause or urea cycle disorder 13.Subjects taking inducers of LTG glucuronidation (i.e., rifampicinor lopinavir/ritonavir), atazanavir/ritonavir, risperidone, or oral contraceptives or hormone drugs containing estrogen 14.Subjects taking carbapenem antibiotic (i.e., panipenem/betamipron, meropenem hydrate, imipenem hydrate/cilastatin sodium, biapenem, doripenem hydrate, or tebipenem pivoxil) 15.Subjects who have participated in other clinical studies within 3 months prior to start of the investigational product 16.Subjects who have had active suicidal plans/intent or suicidal thoughts in the past 3 months prior to start of the investigational product; or subjects who have history of suicide attempts in the last 1 year prior to start of the investigational product or of multiple suicide attempts in their lifetime 17.Subjects whom the investigator or subinvestigator considers ineligible for the study
Trial location(s)
Study documents
Scientific result summary
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2015-11-05
Actual study completion date
2015-11-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website